Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9548959 | 0.81 | AKR1B1 (0.51) | AKR1B1ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL25569811 | 0.81 | AKR1B1 (0.36) | AKR1B1ALDH1A1CYP1A2MAPTCYP2C19 | |
| SCHEMBL25569805 | 0.80 | AKR1B1 (0.38) | AKR1B1ALDH1A1CYP1A2MAPTCYP2C19 | |
| SCHEMBL7241941 | 0.74 | GRIN2B (0.33) | AKR1B1MAPTHPGDLMNA | |
| SCHEMBL25569860 | 0.73 | MTNR1A (0.40) | AKR1B1ALDH1A1MAPTGAA | |
| SCHEMBL25569856 | 0.72 | HDAC4 (0.37) | AKR1B1FAAHALDH1A1MAPTMEN1 | |
| SCHEMBL12694254 | 0.71 | CTSL (0.43) | ALDH1A1CYP1A2MAPTCYP2C19HPGD | |
| SCHEMBL12296552 | 0.71 | IDO1 (0.36) | MAPTLMNA | |
| SCHEMBL1861656 | 0.69 | AKR1B1 (0.50) | AKR1B1ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL25569783 | 0.69 | LMNA (0.35) | AKR1B1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | AKR1B1 3863/4885FAAH 769/4885ALDH1A1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.